InSite Vision Announces Positive Confirmatory Phase 3 Results For Bromsite™ For The Reduction Of Inflammation And Pain After Cataract Surgery

Published: Dec 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced top-line results from its recently completed confirmatory Phase 3 clinical trial of BromSite™ (ISV-303) for the reduction of inflammation and pain after cataract surgery. BromSite combines a low dose (0.075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with InSite Vision’s DuraSite® drug delivery technology.

Help employers find you! Check out all the jobs and post your resume.

Back to news